Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration
Open Access
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 129 (1) , 54-63
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Merck Sharp and Dohme United Kingdom
- Genentech
- Novartis
- Roche
- Biogen
- Boehringer Ingelheim
This publication has 23 references indexed in Scilit:
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized TrialOphthalmology, 2013
- Age‐Related Macular DegenerationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2013
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmologica, 2012
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- Age-related macular degenerationThe Lancet, 2012
- Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature ReviewOphthalmic Research, 2011
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006